Follow The Filings

BIIB Biogen

Biogen earnings company data as of 3:06 PM ET 10/30

  • 1 of 1 EPS beats

History

1 period, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 28 Oct EPS 2.08 2.62 Beat +26.0%
Rev $2.63B $2.80B Beat +6.5%

Insider trades

Open-market buys and sales by BIIB's executives, directors and 10% owners in the last 12 months, from their Form 4s

All BIIB insider trades
  • $585 bought by 1 insider
  • None no sales outside a trading plan
  • $905K sold by 2 insiders under 10b5-1 plans
  1. Lloyd Minor Director
    Planned sale
    $240K 1,186 shares at $202.15 31% of stake
    Traded Aug 3–4 Filed Aug 5
    ↗
  2. Nicole Murphy Head of Pharm Ops and Tech
    Buy
    $585 3 shares at $195.04 +<0.1% to stake
    Traded Feb 12 Filed Feb 17
    ↗
  3. Priya Singhal Head of Development
    Planned sale
    $532K 2,660 shares at $199.83 25% of stake
    Traded Feb 9 Filed Feb 10
    ↗
  4. Priya Singhal Head of Development
    Planned sale
    $134K 748 shares at $179.30 11% of stake
    Traded Feb 2 Filed Feb 3
    ↗

Also filed in the last 12 months, not counted as buying or selling: 33 option exercises, 32 share withholdings for taxes, and 9 stock grants.

SEC filings

Recent issuer filings from EDGAR, 22 shown.

Filed Form Detail Links
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 2.02 Filing Doc
8-K/A 9.01 Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 1.01,2.01,2.03,7.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13D — Filing Doc
8-K 2.02 Filing Doc
8-K 1.01,8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.02 Filing Doc

Source: SEC EDGAR submissions, updated 2 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.